Orexo ABORXOF 34 Market Cap is $82.09 Mil as of Jun. 24, 2026. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Orexo AB ranks worse than 62.37% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Orexo AB's share price for the quarter that ended in Mar. 2026 was $2.2862. Orexo AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 35.13 Mil. Therefore, Orexo AB's market cap for the quarter that ended in Mar. 2026 was $80.31 Mil.
Orexo AB's quarterly market cap
increased
from Sep. 2025 ($100.66 Mil) to Dec. 2025 ($112.11 Mil) but then
declined
from Dec. 2025 ($112.11 Mil) to Mar. 2026 ($80.31 Mil).
Orexo AB's annual market cap
declined
from Dec. 2023 ($41.00 Mil) to Dec. 2024 ($37.27 Mil) but then
increased
from Dec. 2024 ($37.27 Mil) to Dec. 2025 ($112.11 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Orexo AB's Enterprise Value for Today is $42.71 Mil.
Orexo AB (OTCPK:ORXOF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Orexo AB Market Cap Related Terms
Orexo AB Market Cap Historical Data
* Premium members only.
The historical data trend for Orexo AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Orexo AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Orexo AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orexo AB (ORXOF) has a Market Cap of $82.09 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Orexo AB and its competitors. According to the industry distribution chart, Orexo AB ranks #638 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 62.4%.
Is Orexo AB's Market Cap too high?
Orexo AB's current Market Cap is $82.09 Mil. The Drug Manufacturers industry median Market Cap is 207.38. Orexo AB's value of $82.09 Mil is 60.4% below this industry median. Based on the distribution chart, Orexo AB ranks #638 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #638 out of 1023 companies for Market Cap. This places Orexo AB in the lower half of its industry. The industry median Market Cap is 207.38. Orexo AB's value of $82.09 Mil is 60.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 207.38, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Market Cap of $82.09 Mil is 60.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Market Cap is 207.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Market Cap is $82.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current Market Cap is $82.09 Mil and 60.4% below the Drug Manufacturers industry median of 207.38. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Orexo AB (ORXOF), the current Market Cap is $82.09 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOF) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOF:
Market Cap: $82.09 Mil
GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
Industry Position: 60.4% below the Drug Manufacturers median (#638 of 1023)
No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score
Get the complete analysis for ORXOF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOF has been successfully added to your 
